Diamorphine being added to list of opioids (Part B): Notice of amendment

Date: January 14, 2022

This notice of amendment is to notify stakeholders that Health Canada has amended Part B of the List of Opioids.

Specifically, we have added the active ingredient "diamorphine" to Part B of the opioids list. Opioids included in this list are subject to market authorization terms and conditions requiring the submission of a Canadian-specific opioid targeted risk management plan.

The listing in Part B now reads:

• drugs intended for human use containing any of the following active ingredients: diamorphine
• including (but not limited to): diamorphine hydrochloride; diacetylmorphine hydrochloride
• qualifier: none
• effective date: January 14, 2022

If you have any questions on this amendment, please contact the regulatory project management section at:

Marketed Pharmaceuticals Bureau
Marketed Health Products Directorate
Health Canada
Address Locator 1912A
200 Eglantine Dr
Ottawa ON K1A 0K9

E-mail: mpb.rpm-gpr.bppc@hc-sc.gc.ca